semaglutide patent novo nordisk expires next year: faces tough competition in the Chinese obesity market No relief for Novo Nordisk:

Three new NEJM trials highlight the potential of oral GLP-1 therapies for obesity and diabetes

& Hoa, N

Oral formulations may be particularly appropriate for patients with documented needle anxiety or injection-related psychological barriers that would prevent injectable therapy initiation or continuation, individuals whose travel schedules, living situations, or daily routines make weekly injection protocols impractical, those seeking maximum medication discretion where tablet administration offers advantages, patients preferring oral medication based on personal autonomy and comfort considerations, and individuals willing to commit to strict daily dosing protocols required for adequate oral absorption

You know, when youre a junior in the OR youre not really doing the most sophisticated of things anyways

Tirzepatide may offer stronger weight loss and blood sugar control because of its dual action, while semaglutide has a proven track record and is often more affordable at lower doses

This step will protect you from infection